The global lymphoma treatment market size accounted for USD 8.08 billion in 2025 and is forecasted to hit around USD 16.62 billion by 2034, representing a CAGR of 8.34% from 2025 to 2034. The North America market size was estimated at USD 3.73 billion in 2024 and is expanding at a CAGR of 8.53% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Lymphoma Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Lymphoma Treatment Market, by Disease Type
8.1.1. Hodgkin lymphoma (HL)
8.1.1.1. Market Revenue and Forecast
8.1.2. Non-Hodgkin lymphoma (NHL)
8.1.2.1. Market Revenue and Forecast
9.1. Lymphoma Treatment Market, by Therapy Type
9.1.1. Chemotherapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Radiation therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Immunotherapy/ Targeted therapy (small molecules, TKIs, BCL-2 inhibitors)
9.1.3.1. Market Revenue and Forecast
9.1.4. Monoclonal antibodies (naked mAbs)
9.1.4.1. Market Revenue and Forecast
9.1.5. Antibody-drug conjugates (ADCs)
9.1.5.1. Market Revenue and Forecast
9.1.6. Immunomodulators (IMiDs)
9.1.6.1. Market Revenue and Forecast
9.1.7. Immune checkpoint inhibitors
9.1.7.1. Market Revenue and Forecast
9.1.8. Cellular therapies (CAR-T)
9.1.8.1. Market Revenue and Forecast
9.1.9. Stem-cell / bone-marrow transplant
9.1.9.1. Market Revenue and Forecast
9.1.10. Supportive care (growth factors, antiemetics, prophylactics).
9.1.10.1. Market Revenue and Forecast
10.1. Lymphoma Treatment Market, by Drug Class / Mechanism
10.1.1. Anti-CD20 mAbs (e.g., rituximab)
10.1.1.1. Market Revenue and Forecast
10.1.2. CD30 ADCs (e.g., brentuximab)
10.1.2.1. Market Revenue and Forecast
10.1.3. BTK inhibitors (e.g., ibrutinib)
10.1.3.1. Market Revenue and Forecast
10.1.4. BCL-2 inhibitors (e.g., venetoclax)
10.1.4.1. Market Revenue and Forecast
10.1.5. PI3K inhibitors
10.1.5.1. Market Revenue and Forecast
10.1.6. Checkpoint inhibitors (PD-1/PD-L1)
10.1.6.1. Market Revenue and Forecast
10.1.7. CAR-T & other cell therapies
10.1.7.1. Market Revenue and Forecast
10.1.8. Others (HDAC inhibitors, proteasome inhibitors).
10.1.8.1. Market Revenue and Forecast
11.1. Lymphoma Treatment Market, by Line of Therapy
11.1.1. First-line (frontline)
11.1.1.1. Market Revenue and Forecast
11.1.2. Second-line
11.1.2.1. Market Revenue and Forecast
11.1.3. Relapsed / refractory (R/R)
11.1.3.1. Market Revenue and Forecast
11.1.4. Maintenance therapy.
11.1.4.1. Market Revenue and Forecast
12.1. Lymphoma Treatment Market, by Mode of Administration
12.1.1. Intravenous / infusion
12.1.1.1. Market Revenue and Forecast
12.1.2. Subcutaneous
12.1.2.1. Market Revenue and Forecast
12.1.3. Foundries
12.1.3.1. Market Revenue and Forecast
12.1.4. Oral (small molecules)
12.1.4.1. Market Revenue and Forecast
12.1.5. Intrathecal/localized (where applicable).
12.1.5.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease Type
13.1.2. Market Revenue and Forecast, by Therapy Type
13.1.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.1.4. Market Revenue and Forecast, by Line of Therapy
13.1.5. Market Revenue and Forecast, by Mode of Administration
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease Type
13.1.6.2. Market Revenue and Forecast, by Therapy Type
13.1.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.1.6.4. Market Revenue and Forecast, by Line of Therapy
13.1.6.5. Market Revenue and Forecast, by Mode of Administration
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Disease Type
13.1.7.2. Market Revenue and Forecast, by Therapy Type
13.1.7.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.1.7.4. Market Revenue and Forecast, by Line of Therapy
13.1.7.5. Market Revenue and Forecast, by Mode of Administration
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease Type
13.2.2. Market Revenue and Forecast, by Therapy Type
13.2.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.4. Market Revenue and Forecast, by Line of Therapy
13.2.5. Market Revenue and Forecast, by Mode of Administration
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease Type
13.2.6.2. Market Revenue and Forecast, by Therapy Type
13.2.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.7. Market Revenue and Forecast, by Line of Therapy
13.2.8. Market Revenue and Forecast, by Mode of Administration
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease Type
13.2.9.2. Market Revenue and Forecast, by Therapy Type
13.2.9.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.10. Market Revenue and Forecast, by Line of Therapy
13.2.11. Market Revenue and Forecast, by Mode of Administration
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease Type
13.2.12.2. Market Revenue and Forecast, by Therapy Type
13.2.12.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.12.4. Market Revenue and Forecast, by Line of Therapy
13.2.13. Market Revenue and Forecast, by Mode of Administration
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease Type
13.2.14.2. Market Revenue and Forecast, by Therapy Type
13.2.14.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.2.14.4. Market Revenue and Forecast, by Line of Therapy
13.2.15. Market Revenue and Forecast, by Mode of Administration
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease Type
13.3.2. Market Revenue and Forecast, by Therapy Type
13.3.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.4. Market Revenue and Forecast, by Line of Therapy
13.3.5. Market Revenue and Forecast, by Mode of Administration
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease Type
13.3.6.2. Market Revenue and Forecast, by Therapy Type
13.3.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.6.4. Market Revenue and Forecast, by Line of Therapy
13.3.7. Market Revenue and Forecast, by Mode of Administration
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease Type
13.3.8.2. Market Revenue and Forecast, by Therapy Type
13.3.8.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.8.4. Market Revenue and Forecast, by Line of Therapy
13.3.9. Market Revenue and Forecast, by Mode of Administration
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease Type
13.3.10.2. Market Revenue and Forecast, by Therapy Type
13.3.10.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.10.4. Market Revenue and Forecast, by Line of Therapy
13.3.10.5. Market Revenue and Forecast, by Mode of Administration
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease Type
13.3.11.2. Market Revenue and Forecast, by Therapy Type
13.3.11.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.3.11.4. Market Revenue and Forecast, by Line of Therapy
13.3.11.5. Market Revenue and Forecast, by Mode of Administration
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease Type
13.4.2. Market Revenue and Forecast, by Therapy Type
13.4.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.4. Market Revenue and Forecast, by Line of Therapy
13.4.5. Market Revenue and Forecast, by Mode of Administration
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease Type
13.4.6.2. Market Revenue and Forecast, by Therapy Type
13.4.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.6.4. Market Revenue and Forecast, by Line of Therapy
13.4.7. Market Revenue and Forecast, by Mode of Administration
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease Type
13.4.8.2. Market Revenue and Forecast, by Therapy Type
13.4.8.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.8.4. Market Revenue and Forecast, by Line of Therapy
13.4.9. Market Revenue and Forecast, by Mode of Administration
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease Type
13.4.10.2. Market Revenue and Forecast, by Therapy Type
13.4.10.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.10.4. Market Revenue and Forecast, by Line of Therapy
13.4.10.5. Market Revenue and Forecast, by Mode of Administration
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease Type
13.4.11.2. Market Revenue and Forecast, by Therapy Type
13.4.11.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.4.11.4. Market Revenue and Forecast, by Line of Therapy
13.4.11.5. Market Revenue and Forecast, by Mode of Administration
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease Type
13.5.2. Market Revenue and Forecast, by Therapy Type
13.5.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.5.4. Market Revenue and Forecast, by Line of Therapy
13.5.5. Market Revenue and Forecast, by Mode of Administration
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease Type
13.5.6.2. Market Revenue and Forecast, by Therapy Type
13.5.6.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.5.6.4. Market Revenue and Forecast, by Line of Therapy
13.5.7. Market Revenue and Forecast, by Mode of Administration
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease Type
13.5.8.2. Market Revenue and Forecast, by Therapy Type
13.5.8.3. Market Revenue and Forecast, by Drug Class / Mechanism
13.5.8.4. Market Revenue and Forecast, by Line of Therapy
13.5.8.5. Market Revenue and Forecast, by Mode of Administration
14.1. F. Hoffmann-La Roche (Roche)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Novartis • Gilead Sciences (Kite/Gilead)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bristol-Myers Squibb
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Pfizer (Seagen/Acquisitions)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. AstraZeneca
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Bayer
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. BeiGene
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Johnson & Johnson (Janssen)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. AbbVie
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Takeda
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description